- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Biodexa Pharmaceuticals PLC DRC (BDRX)
Assess today's live Biodexa Pharmaceuticals PLC DRC (BDRX) share price, performance and insights using our live NASDAQ: BDRX stock exchange data.
Analyse the historical data and Biodexa Pharmaceuticals PLC DRC share price performance charts on this page. Our technical summary section provides analysis on Biodexa Pharmaceuticals DRC share price buy/sell indicators using real-time data (or discuss the Biodexa Pharmaceuticals DRC (BDRX) stock price today with other investors in the Biodexa Pharmaceuticals DRC NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ BDRX share price (ISIN: US59564R8723) to enhance your trading decisions with our free investment tools and resources.
What Is the Biodexa Pharmaceuticals PLC DRC Share Price Today?
The Biodexa Pharmaceuticals DRC share price today is 4.670.
What Is the Stock Symbol for Biodexa Pharmaceuticals PLC DRC
The stock symbol (or 'ticker') for Biodexa Pharmaceuticals PLC DRC is "BDRX."
What Stock Exchange Does Biodexa Pharmaceuticals PLC DRC Trade On?
Biodexa Pharmaceuticals PLC DRC is listed and trades on the NASDAQ stock exchange.
Is Biodexa Pharmaceuticals PLC DRC a Good Stock to Buy?
Determining whether Biodexa Pharmaceuticals PLC DRC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Biodexa Pharmaceuticals PLC DRC share price performance charts on this page. Our technical summary section provides analysis on Biodexa Pharmaceuticals DRC share price buy/sell indicators using real-time data (or discuss the Biodexa Pharmaceuticals DRC (BDRX) stock price today with other investors in the Biodexa Pharmaceuticals DRC NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ BDRX share price (ISIN: US59564R8723) to enhance your trading decisions with our free investment tools and resources.
What Is the Biodexa Pharmaceuticals PLC DRC Share Price Today?
The Biodexa Pharmaceuticals DRC share price today is 4.670.
What Is the Stock Symbol for Biodexa Pharmaceuticals PLC DRC
The stock symbol (or 'ticker') for Biodexa Pharmaceuticals PLC DRC is "BDRX."
What Stock Exchange Does Biodexa Pharmaceuticals PLC DRC Trade On?
Biodexa Pharmaceuticals PLC DRC is listed and trades on the NASDAQ stock exchange.
Is Biodexa Pharmaceuticals PLC DRC a Good Stock to Buy?
Determining whether Biodexa Pharmaceuticals PLC DRC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
4.670
+0.190(+4.24%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.210
4.750
52 wk Range
2.860
96.500
BDRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.2104.750
52 wk Range
2.86096.500
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BDRX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Earnings
Latest Release
27/03/2026
EPS / Forecast
-3.05 / --
Revenue / Forecast
-- / --
Compare BDRX to Peers and Sector
Metrics to compare | BDRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBDRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.3x | −22.0x | −0.5x | |
PEG Ratio | - | 0.05 | 0.00 | |
Price/Book | 0.2x | 4.5x | 2.6x | |
Price / LTM Sales | - | 73.0x | 3.2x | |
Upside (Analyst Target) | - | 83.7% | 47.8% | |
Fair Value Upside | Unlock | −24.3% | 5.9% | Unlock |
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTX240, for the treatment of gastrointestinal stromal tumors. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, nanotechnology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours; and MidaCore, a gold nanoparticle used for targeting sites of disease. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
People Also Watch
FAQ
What Is the Biodexa Pharmaceuticals DRC (NASDAQ: BDRX) Share Price Today?
The Biodexa Pharmaceuticals DRC stock price today is 4.670 USD.
What Stock Exchange Does Biodexa Pharmaceuticals DRC (BDRX) Trade On?
Biodexa Pharmaceuticals DRC is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Biodexa Pharmaceuticals DRC?
The stock symbol (also called a 'ticker') for Biodexa Pharmaceuticals DRC is "BDRX."
What Is the Current Biodexa Pharmaceuticals DRC Market Capitalisation?
As of today, Biodexa Pharmaceuticals DRC (NASDAQ: BDRX) market cap is 2.900M USD.
What Is Biodexa Pharmaceuticals DRC's (BDRX) Earnings Per Share (TTM)?
The Biodexa Pharmaceuticals DRC EPS is currently -58.183 (Trailing Twelve Months).
Is BDRX a Buy or Sell From a Technical Analyst Perspective?
Based on today's Biodexa Pharmaceuticals DRC moving averages and other technical indicators, the daily buy/sell signal for BDRX stock is Strong Buy.
How Many Times Has Biodexa Pharmaceuticals DRC Stock Split?
Biodexa Pharmaceuticals DRC has split 8 times. (See the BDRX stock split history page for full effective split date and price information.)
How Many Employees Does Biodexa Pharmaceuticals DRC Have?
Biodexa Pharmaceuticals DRC has 11 employees, based on their latest Companies House report.
What is the current trading status of Biodexa Pharmaceuticals DRC (NASDAQ: BDRX)?
As of 06/05/2026, Biodexa Pharmaceuticals DRC (BDRX) is trading at a share price of 4.670 USD, with a previous close of 4.480 USD. The stock has fluctuated within a day range of 4.210 USD to 4.750 USD, while its 52-week range spans from 2.860 USD to 96.500 USD.
What Is Biodexa Pharmaceuticals DRC (BDRX) Price Target According to Analysts?
The average 12-month price target for Biodexa Pharmaceuticals DRC is 36.055 USD, with a high estimate of 36.05488385 USD and a low estimate of 36.05488385 USD. 0 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +672.05% Upside potential.
What Is the BDRX Premarket Price?
BDRX's last pre-market stock price is 4.500 USD. The pre-market share volume is 89,260.000, and the stock has decreased by 0.020, or 0.450%.
What Is the BDRX After Hours Price?
BDRX's last after hours stock price is 4.180 USD, the stock has decreased by -0.300, or -6.700%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.